Tempest Therapeutics, Inc. (TPST)
Data as of , from SEC Form 4 filings.
See up to 3 months of TPST. The 7-day demo opens the 1M and 3M ranges and puts TPST on your watchlist.
Start 7-day demoLatest TPST insider trades
About Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
- BRISBANE, CA
- 4
- 2021
- Nasdaq
TPST Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 25,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
TPST insider transactions (Form 4)
1412 Form 4 filings on record, the earliest from Jan 28, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nancy Freda Smith - Director | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Matthew Angel - Officer | Open-market purchase | Common Stock | 231,482 | $2.16 footnote F2 | $500K | |
| Matthew Angel - Officer | Open-market purchase | Series A Warrant (right to buy) | 231,482 | - footnote F2 | - | |
| Matthew Angel - Officer | Open-market purchase | Series B Warrant (right to buy) | 231,482 | - footnote F2 | - | |
| ||||||
| John D. Yee | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| William Drake Richey | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
 Justin Trojanowski - Officer | Grant or award | Employee Stock Option (right to buy) | 22,000 | $0.00 | - | |
 Nicholas Maestas - Officer | Grant or award | Employee Stock Option (right to buy) | 140,000 | $0.00 | - | |
| Matthew Angel - Officer | Open-market purchase | Common Stock | 231,482 | $2.16 | $500K | |
| Matthew Angel - Officer | Grant or award | Employee Stock Option (right to buy) | 269,621 | $0.00 | - | |
 Ronit Simantov | Grant or award | Stock Option (right to buy) | 1,230 | $0.00 | - | |
| Geoffrey Nichol | Grant or award | Stock Option (right to buy) | 1,230 | $0.00 | - | |
 Michael Raab | Grant or award | Stock Option (right to buy) | 1,230 | $0.00 | - | |
 Christine A. Pellizzari | Grant or award | Stock Option (right to buy) | 1,230 | $0.00 | - | |
TPST insider trading FAQ
What is the latest insider trade for TPST?
Tempest Therapeutics, Inc. (TPST) had 1 insider filing in the last 90 days, with the most recent on 2 October 2026. The full record for TPST runs to 12 Form 4 filings, the earliest from 28 January 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TPST stock?
No insider purchases of TPST were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling TPST stock?
No insider sales of TPST were filed in the last 90 days.
Where can I see TPST SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TPST Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Nancy Freda Smith view on EDGAR
- - Matthew Angel view on EDGAR
- - John D. Yee view on EDGAR
- - William Drake Richey view on EDGAR
- - Justin Trojanowski view on EDGAR
- - Nicholas Maestas view on EDGAR
- - Matthew Angel view on EDGAR
- - Matthew Angel view on EDGAR
- - Ronit Simantov view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where TPST's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TPST with a 7-day demo
- TPST on your watchlist
- Every TPST Form 4 filing on record
- Up to 3 months of TPST price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
